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Patient and disease characteristics
Case No 1 2 3 4 5 6 7
Age 21 45 4 42 46 12 29
Diagnosis CML-CP AML JMML AML CML -BC AML SAA
Conditioning
regimen
FLU-MEL Flu-Busulfan Flu-Bu-Mel FLA+Ara-C+Ida+Mel Flu-Mel Flu-Mel-Ara-c-ATG Flu-CY
Risk factor High Ferritin Haplo-HSCT High Ferritin,
MUD HSCT
High Ferritin
VOD on day 11 11 12 14 14 14 16
Maximal Bilirubin 3.8 5 1.2 1.4 3.2 1.34 3.1
Weight gain (%) 5 22 10 7.5 5 3 13
Bearman score 10 10 20 16 12 11 16
DF Dose mg/kg/d 5 7 7 5 10 10 10
Duration 6 12 10 6 8 8 12
Resolution by D+17 D+28 D+21 D+20 D+22 D+10 D+24
Organ
dysfunctioon
hepatic
encephalopathy
Oxygen
desaturation
renal failure,
hepatic encephalopathy,
Oxygen desaturation
Oxygen
desaturation
renal dysfunction,
hepatic encephalopathy,
oxygen desaturation
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S191patients received DF in doses ranging from 5 mg /kg/d to 10
mg/kg/d in two divided doses for median of 8 days (range 6
to12 days). Six patients received intravenous DF while 1
patient received oral DF. All patients had complete resolution
of VOD by day +22 post transplant (range day + 17 to day
+28). No dose response relationship was observed between
DF dose and time to resolution of VOD. None developed any
side effects of DF.
Conclusion: A lower dose of DF is effective and safe in treat-
ment of moderate VOD. This is especially relevant in a limited
resource setting, however needs prospective evaluation.
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Background: Following hematopoietic stem cell trans-
plantation (HSCT), the probability that acquired protective
immunity is lost over time is signiﬁcant. Therefore, a sys-
tematic reimmunization is important to re-establish appro-
priate immunity and to decrease the risk of vaccine
preventable infectious diseases with their related morbidity
and mortality. The aim of this study is to investigate whether
the recommendations for vaccination were followed in our
hospital and to which extent of conformity they were used.
Methodology: A 2-year retrospective survey, including adult
allogeneic HSCT patients, (transplanted) at the Ghent Uni-
versity Hospital, Belgium, who were at least 3 months post
transplant. Administration of the ﬁrst dose of conjugated
polysaccharide vaccine against Pneumococci was studied.
Results: Data on vaccination schedules of 50 allogeneic
transplantations were collected. Of these, 34 patients (68,0%)
were eligible for recommended vaccinations. Patients were
vaccinated on-schedule (i.e. time-frame between HSCT and
vaccination as recommended in the hospital guideline) in
76,5% (26/34). Postponed vaccination with a medical indi-
cationwas observed in 8,8% (3/34) of patients. Of them, 66,7%
(2/3) were postponed because of infection and 33,3% (1/3)
because of signiﬁcant thrombocytopenia.
Postponed vaccination without a medical excuse was
observed in a minority of the patients, i.e. 11,8% (4/34), with
either ‘no medical reason’ in 75,0% (3/4) or nonadherence in
25,0% of patients (1/4). Postponed vaccination with initialmedical indication but then followed by non-medical reason
was observed in 2,9% (1/34) of patients. Vaccination data
were not available for 32,0% (16/50) of patients. The reasons
were death before start of vaccination in 75,0% (12/16), graft
failure in 12,5% (2/16) and lack of information in 12,5% (2/16)
of patients.
Conclusion: The results emphasize the need for close follow-
up of post-transplant patients in our hospital. This is
conﬁrmed by satisfactory concordance between the hospital
recommendation and vaccination of HSCT patients. Health-
care providers play a crucial role by effectively and appro-
priately following the vaccination schedules. Moreover,
literature data demonstrate that actively involving the pa-
tient in the follow-up (e.g. providing them with their vacci-
nation schedule) results in improved follow-up. The role of a
personalized electronic alert systemwill be explored in near
future. In addition, the appropriate follow-up of out-patient
vaccination, 1 year after HSCT, will be studied.
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Foscarnet (FOS) remains the primary antiviral option in the
setting of intolerance of and/or resistance to ganciclovir (GCV)
and other inhibitors of viral kinase. However, FOS-associated
nephrotoxicity often limits it utility. Because this nephrotox-
icity can be attenuated by substantially increasing the infusion
time and ensuring adequate hydration, we report a successful
approach to the administration of FOS as a continuous infu-
sion (CI) in both the inpatient and outpatient settings. The
decision regarding administering FOS as a CI was solely at the
discretion of the treating team with most common reasons
cited as attenuation of nephrotoxicity, management of ﬂuid
balance, and facilitation of outpatient care.
Results: Data regarding both groups is summarized in Table
1. Throughout administration, total daily dose was adjusted
per recommendations based on creatinine clearance and
adjusted ideal body weight with an additional liter of
hydration daily. Median duration of treatment was 23 days
(4-123d). 22 of the 25 treatment courses (23 patients)
resulted in successful resolution of the disease process;
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S192however, 3 patients died with a detectable viral load despite
the concomitant administration of ganciclovir in 2 patients.
The median serum creatinine (SCr) (mg/dl, range) prior to,
during, and post-FOS CI were 1.3 (0.7-2.2), 1.15 (0.7-2.0), and
1.9 (0.9-7.1), respectively. In the analysis of individual data,
median net change in SCr was 0.3 mg/dl (range: -0.9 to +5.7)
from the pre- to the post-FOS period, although one patient
developed renal failure shortly before dying of multi-organ
failure, GVHD and persistent CMV disease.
Conclusion: FOS CI permitted the safe administration of
outpatient treatment in patients at high risk for nephrotox-
icity with CMV reactivation and/or disease which, in our
experience, has increased the utility of this drug. Data
regarding comparative efﬁcacy to standard infusion will
require additional study.285
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Background: Romiplostim is a thrombopoietin receptor
agonist utilized in the treatment of pediatric patients with
immune thrombocytopenia. Furthermore, the limited
toxicity of romiplostim makes this an attractive option for
the treatment of post-HSCT immune thrombocytopenia. We
describe a 3-year-old male with X-linked chronic granulo-
matous disease (CGD) treated with unrelated donor HSCT.
His course was complicated by immune dysregulation
manifest as recurrent pleural effusions that improved with
corticosteroids. At 1-year post HSCT, after stopping his cor-
ticosteroids he developed symptomatic thrombocytopenia
and autoimmune hemolytic anemia (AIHA). He was started
on romiplostimwith improvement in his thrombocytopenia.
Methods: A 3-year-old Asian male was diagnosed with
X-CGD. The patient underwent HSCT utilizing a 9/10 HLA
matched unrelated female donor. The preparative regimen
was: busulfan (0.8 mg/kg/dose x 16 doses), cytoxan (50 mg/
kg/dose x 4 doses), ﬂudarabine (30mg/m2) and Campath
(2 mg x 4 doses). Graft-versus-host disease prophylaxis was:
cyclosporine and methotrexate. Post-HSCT he developed
seizures and mucositis. He engrafted on Day +18 with 100%
donor engraftment. On Day +62 and +119 he presented with
symptomatic pleural effusions. Evaluation for infectious
pathogens was negative. On both occasions a response to
corticosteroids was documented. At 1-year post-HSCT as his
corticosteroid taper ﬁnished he developed symptomatic
thrombocytopenia (platelet count 5,000 / uL).
Results: He was treated with intravenous immunoglobulin
and platelet transfusion without signiﬁcant improvement. In
addition to symptomatic thrombocytopenia a warm AIHA
(hemoglobin 5.2 g / dL) emerged. Evaluation for infectious
pathogens was negative. A bone marrow examination
demonstrated a cellular marrow with trilineage hemato-
poiesis, megakaryocytic hypoplasia, and erythroid hyper-
plasia. Cytogenetic evaluation demonstrated a normal male
karyotype and chimerism studies documented 98% donor
engraftment. In order to avoid the toxicity associated with
corticosteroid use romiplostim was started at 5 mcg/kg
subcutaneous each week. Within three 3 weeks of starting
therapy his platelet count was> 50,000 / uL. He continues to
maintain a platelet count > 100,000 / uL while tapering hisromiplostim dose. His hemoglobin also continued to improve
without a need for transfusion support.
Conclusion: To our knowledge, this is the ﬁrst description of a
successful application of romiplostim as initial therapy in a
pediatric patient with immune thrombocytopenia following
matched unrelated donor HSCT for X-linked CGD. We found
that the use of romiplostim to be an effective and safe alter-
native to thepotentialmorbidityandmortality associatedwith
the use of immunosuppressive agents such as corticosteroids.286
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Hematopoietic progenitor stem cell transplantation (HSCT)
has different stages; the presence of anxiety and psycho-
logical disorders is frequently reported. Objective. To assess
and compare the patient’s psychological state before and
after HSCT, evaluating the level of anxiety, emotional in-
dicators and external variables which inﬂuence the psycho-
logical state. Method. First stage, pre- HSCT, 70 patients were
assessed: 26 females and 44 males, from the Oncological,
Hematological and Immunological departments. Age: 6-18
years old, appropriate for tests. Registration: age, gender,
diagnosis, date of diagnosis, hospital stay and family dy-
namics. Standardized psychological tests and semi-struc-
tured interview. Second stage, post- HSCT. Same assessment
but with 18 patients. Results. 70% of patients showed social
concerns. With regards to their family, most of them had at
least 2 emotional indicators. Most patients with high pre-
HSCT decreased their anxiety levels during the post- HSCT,
while most of the ones with low anxiety remained the same.
Conclusions. Psychological assessment and preparation in-
creases the possibility of knowing variables that inﬂuence
the patient’s emotional status and create a treatment plan
appropriate for him/her.287
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Background: Since the inception of the pediatric transplant
program at the University of Mississippi Medical Center
(UMMC), intravenous gammaglobulin (IVIG) has been given
biweekly prophylactically post- transplant for up to 100 days
post transplantation. Many authors now report a lack of ef-
ﬁcacy in administering IVIG for this purpose and perhaps
adverse events such as infection, reaction, and even a higher
risk of veno-occlusive disease.
Methods: As a performance improvement project, a retro-
spective chart audit was completed to measure actual levels
of immunoglobulin G (IgG) in our transplant patients to see if
low levels of immunoglobulin G (IGG) could be identiﬁed.
Patients were characterized by age (at time of transplant),
